Literature DB >> 9119192

Reduced intracellular accumulation of azole antifungal results in resistance in Candida albicans isolate NCPF 3363.

D C Lamb1, D E Kelly, N J Manning, S L Kelly.   

Abstract

Candida albicans strain NCPF 3363 was isolated from a British patient with chronic mucocutaneous candidiasis (CMC) and confirmed to be resistant to azole antifungal compounds. In this study we investigate the molecular basis of resistance and show that azole tolerance in NCPF 3363 was associated with reduced intracellular accumulation of drug and not reduced affinity for the target site, as previously indicated. Relative impermeability or the presence of transporters related to those responsible for multidrug resistance are implicated in the mechanism of resistance.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9119192     DOI: 10.1111/j.1574-6968.1997.tb10240.x

Source DB:  PubMed          Journal:  FEMS Microbiol Lett        ISSN: 0378-1097            Impact factor:   2.742


  3 in total

Review 1.  Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

Authors:  T C White; K A Marr; R A Bowden
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

2.  Reduced azole susceptibility in genotype 3 Candida dubliniensis isolates associated with increased CdCDR1 and CdCDR2 expression.

Authors:  Emmanuelle Pinjon; Colin J Jackson; Steven L Kelly; Dominique Sanglard; Gary Moran; David C Coleman; Derek J Sullivan
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

3.  Azole drugs are imported by facilitated diffusion in Candida albicans and other pathogenic fungi.

Authors:  Bryce E Mansfield; Hanna N Oltean; Brian G Oliver; Samantha J Hoot; Sarah E Leyde; Lizbeth Hedstrom; Theodore C White
Journal:  PLoS Pathog       Date:  2010-09-30       Impact factor: 6.823

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.